C4 Therapeutics reports Q2 2026 results, cemsidomide trials on track for 2027 data

C4 Therapeutics reported second quarter 2026 financial results and pipeline updates on August 11, 2026 for its lead candidate cemsidomide, an oral IKZF1/3 degrader in development for multiple myeloma.

The company said its Phase 2 MOMENTUM study, which pairs cemsidomide with dexamethasone in patients with late-line multiple myeloma, is on track to complete enrollment in the first quarter of 2027, with initial investigator-assessed overall response rate data expected in the second half of 2027.¹ A separate Phase 1b trial combining cemsidomide and dexamethasone with the bispecific antibody elranatamab (ELREXFIO) in earlier lines of treatment continues to progress, with a dose escalation update expected in the second half of 2026 and data from all cohorts expected in mid-2027.¹

C4T also said it has started activities for an additional Phase 1b trial testing cemsidomide in two arms, one paired with daratumumab and one with carfilzomib, in relapsed/refractory patients, with initiation expected in the first half of 2027.¹

At the EHA 2026 Congress, the company presented updated Phase 1 data showing a 40% overall response rate at the 75 microgram dose and 53% at the 100 microgram dose, including one stringent complete response and two complete responses, with two patients reaching minimal residual disease negativity and no cemsidomide-related discontinuations across doses.¹

On the business side, C4T entered a new collaboration with Roche in April 2026 to develop degrader-antibody conjugates, receiving a $20 million upfront payment in May 2026.¹ The company also raised approximately $33.5 million in net proceeds during the quarter through its at-the-market program.¹

Cash, cash equivalents and marketable securities totaled $300.4 million as of June 30, 2026, up from $268.3 million at the end of the first quarter, and the company said this is expected to fund operations to the end of 2028.¹